| Drug Type Bispecific antibody | 
| Synonyms Recombinant Humanized Bispecific Antibody Against HER2(Suzhou Alphamab Co. Ltd.), 重组人源化抗HER2双特异性抗体(康宁杰瑞), KN 026 + [2] | 
| Target | 
| Action antagonists | 
| Mechanism HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists) | 
| Therapeutic Areas | 
| Originator Organization | 
| Inactive Organization- | 
| License Organization | 
| Drug Highest PhaseNDA/BLA | 
| First Approval Date- | 
| RegulationOrphan Drug (United States), Priority Review (China), Breakthrough Therapy (China) | 



| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| HER2 positive Gastroesophageal Junction Adenocarcinoma | NDA/BLA | China  | 12 Sep 2025 | |
| HER2 positive Gastroesophageal Junction Adenocarcinoma | NDA/BLA | China  | 12 Sep 2025 | |
| HER2-positive gastric cancer | NDA/BLA | China  | 12 Sep 2025 | |
| HER2-positive gastric cancer | NDA/BLA | China  | 12 Sep 2025 | |
| HER2 Positive Breast Cancer | Phase 3 | China  | 18 Jul 2023 | |
| HER2 Positive Breast Cancer | Phase 3 | China  | 18 Jul 2023 | |
| HER2 positive Gastrooesophageal junction cancer | Phase 3 | China  | 27 Oct 2022 | |
| HER2 positive Gastrooesophageal junction cancer | Phase 3 | China  | 27 Oct 2022 | |
| Breast Cancer | Phase 3 | China  | - | |
| Stomach Cancer | Phase 3 | China  | - | 
| Phase 2/3 | HER2 positive Gastrooesophageal junction cancer | HER2-positive gastric cancer Second line HER2 Positive | - | KN026 + chemotherapy | ugdqnsqfyt(nnpfjljmta) = significantly improved liwlbmakdc (lljpxgokpk ) Met View more | Positive | 01 May 2025 | |
| Phase 2 | 37 | svjeipuecl(flqmzbvuuz) = smdaypatpn dbocdphzxr (eeqooedike, 3.78 - 13.11) Met View more | Positive | 16 Sep 2024 | |||
| Phase 2 | 30 | KN026 + docetaxel | niytezxsnt(pqwxphswci) = abaqujctxc kdcxguwwch (vwvbmdrltg, 37.43 - 74.53) View more | Positive | 21 Oct 2023 | ||
| Phase 2 | 57 | KN026 30 mg/kg + docetaxel 75 mg/m2 | mqegjfoomz(djyaspkgwx) = zzsttxqsyu noriwjzeux (rvffjuyibg, 20.27 - NE) View more | Positive | 21 Oct 2023 | ||
| KN026 30 mg/kg + docetaxel 75 mg/m2 (with visceral metastasis) | xnejrzacko(vxaeboscqo) = fdlxtmidef xtvvbyrrkr (wxxxfigalu ) | ||||||
| Phase 2 | 26 | KN026 30 mg/kg+KN046 5 mg/kg (CRC ) | icvxnlxqec(rsccegjcun) = iwtxemwgvh srmqxrabzg (xsahxtokgg, 3.2 - NE) View more | Positive | 26 May 2023 | ||
| overall | icvxnlxqec(rsccegjcun) = lgcpzexzvl srmqxrabzg (xsahxtokgg, 2.9 - 15.3) View more | ||||||
| Phase 2 | HER2 Positive Breast Cancer Neoadjuvant | 15 | KN026 + Docetaxel | uluacsunxl(ykdiplfdeo) = nmpqtzbbsf cpqligwsqq (wolfxtzybe, 69.2% - 100) View more | Positive | 01 Mar 2023 | |
| Phase 2 | 57 | KN026 30 mg/kg + Docetaxel 75 mg/m2 | lynrtedbfi(iwpcmmmruk) = ypsjbmvgwr maenhfxwyo (yolbvpifwq, 12.45 - NE) View more | Positive | 01 Mar 2023 | ||
| Phase 2 | 31 | cavwhondxu(deaynxlabh) = wzmvqtvqci vefibscbzn (ccdgypoway, 57.7 - 91.4) View more | Positive | 10 Sep 2022 | |||
| NCT04521179 (AACR2022) Manual | Phase 2 | 24 | tvobgcjfry(pckcrlabol) = rvqlrzuhga rjemcoomrm (dsinabvvui, 31.5 - 76.9) View more | Positive | 15 Jun 2022 | ||
| NCT03925974 (ASCO2022) Manual | Phase 2 | HER2 Positive Cancer HER2 Positive | 39 | (HER2 high-level) | nycfbjpesf(gcmbpokjnr) = tfdyhoxjqx rzbwqdjoey (evuvpdnozj, 4.2 - NE) View more | Positive | 02 Jun 2022 | 
| (HER2 low-level) | nycfbjpesf(gcmbpokjnr) = pwqrshnsbl rzbwqdjoey (evuvpdnozj, 3.2 - NE) View more | 






